Navigation Links
Eprodisate in Medical News

Neurochem moves eprodisate (KIACTA(TM)) drug development program forward for Amyloid A amyloidosis

ECUBLENS, SWITZERLAND, March 13 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX ; TSX: NRM), announces that the Company is taking new initiatives to pursue the drug development program for its investigational pr...

Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis

ECUBLENS, Switzerland, Dec. 14 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX ; TSX: NRM), announces that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medi...

Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review

ECUBLENS, Switzerland, Dec. 6 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ: NRMX ; TSX: NRM), announces that the Company has received an acknowledgement from the United States Food and Drug Administration (FDA) tha...

BELLUS Health reports results for first quarter of fiscal 2009

...revenue (non-monetary liability) to accrued liability (monetary liability) following the recovery by the Company of ownership rights in and control of eprodisate (KIACTA(TM)). Other income amounted to $529,000 for the current quarter, compared to $278,000 for the same quarter the previous year. Other incom...

BELLUS Health reports results for the fourth quarter of 2008

...ement with Centocor, Inc. (Centocor) in respect of eprodisate (KIACTA(TM)), an oral investigational product cand...ision to continue the drug development program for eprodisate (KIACTA(TM)) and that it will initiate a second Phase III clinical trial for eprodisate (KIACTA(TM)) in close cooperation with the US Food...

BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update

...arily due to funds used in operating activities. eprodisate (KIACTA(TM)) for the treatment of Amyloid A (AA) amyloidosis With respect to eprodisate (KIACTA(TM)), the Company submitted a proposed pro...II trial, should be sufficient to gain approval of eprodisate (KIACTA(TM)) for the treatment of AA Amyloidosis,....

BELLUS Health provides update on activities

...lic syndrome and Alzheimer's disease. The Company expects to file the Investigational New Drug application for the second Phase III clinical trial for eprodisate (KIACTA(TM)) for the treatment of Amyloid A amyloidosis in the fourth quarter of 2008. With respect to this second Phase III KIACTA(TM) clinical tri...

BELLUS HEALTH reports results for first quarter of fiscal 2008

...ement with Centocor, Inc. (Centocor) in respect of eprodisate (KIACTA(TM)), an oral investigational product cand...ecision to pursue the drug development program for eprodisate (KIACTA(TM)) and that it will initiate a second Phase III clinical trial for eprodisate (KIACTA(TM)) in close cooperation with the U.S. Fo...

At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)

...also learn that Neurochem has regained full ownership rights and control on eprodisate (KIACTA(TM)) from Centocor Inc., a wholly owned subsidiairy of Johnson and ...ly announced, Neurochem will initiate a second Phase III clinical trial for eprodisate (KIACTA(TM)) in close cooperation with the U.S. Food and Drug Administratio...

Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives

...n July 2007 for the New Drug Application (NDA) for eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis i... the marketing authorization application (MAA) for eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis i...ts of costs reimbursable by Centocor in respect of eprodisate (KIACTA(TM))-related activities. The Company earns...
Eprodisate in Medical Technology

Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA) Treatment for Patients with Amyloid A (AA) Amyloidosis

ECUBLENS, SWITZERLAND, June 07, 2007 /PRNewswire-FirstCall/ - Neurochem (International) Limited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. , announces that the New England Journal of Medicine (NEJM) published the results of the "Eprodisate For AA Amyloidosis Trial" (EFAAT), recognize...

At the 2007 Alzheimer's Association International Conference on the Prevention of Dementia - Neurochem's U.S. Principal Investigator Presents Update on Tramiprosate (Alzhemed)

...t Neurochem Neurochem Inc. is focused on the development and commercialization of innovative therapeutics to address critical unmet medical needs. eprodisate (KIACTA(TM)) is currently being developed for the treatment of Amyloid A (AA) amyloidosis, and is under regulatory review for marketing approval by th...
Other Tags
(Date:8/28/2014)... Ariz. (PRWEB) August 28, 2014 Arizona ... Force Impact Technologies , has been named one of ... the Year competition. , This is the fourth consecutive ... in the competition. Jared Schoepf, co-founder of SafeSIPP, and ... 2013 and 2012, respectively. In 2011, ASU dominated the ...
(Date:8/28/2014)... Reinberg HealthDay Reporter THURSDAY, ... the diet may worsen symptoms of multiple sclerosis (MS), a ... MS, such as vitamin D, smoking and Epstein Barr virus ... another environmental factor affecting MS patients," said lead researcher Dr. ... in Buenos Aires. Multiple sclerosis is a disease of ...
(Date:8/28/2014)... and Ann Arbor, MI (PRWEB) August 28, 2014 ... company and the nation’s leading intraoperative neurophysiology monitoring ("IONM") ... and CFO, to the position of Chief Executive Officer ... CFO, was promoted to President and CFO in 2013 ... growth and success. , “Bill’s efforts and achievements ...
(Date:8/28/2014)... Mount Vernon, Ind. (PRWEB) August 28, 2014 ... subsidiary of Valero Energy Corporation (NYSE: VLO), and the ... other state and local officials today at a Port ... recently purchased Mount Vernon ethanol plant. , “The opening ... Indiana-Mount Vernon is another economic development win for ...
(Date:8/28/2014)... Norton HealthDay Reporter THURSDAY, ... sending electrical currents through the scalp to a specific network ... a day. In a small study of healthy young ... certain networks involved in memory. That, in turn, boosted participants, ... after the brain stimulation. During TMS, an electromagnetic coil ...
Breaking Medicine News(10 mins):Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 3Health News:Could Too Much Salt Harm MS Patients? 2Health News:Could Too Much Salt Harm MS Patients? 3Health News:Biotronic NeuroNetwork Announces the Promotion of Bill Gecsey to CEO 2Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 2Health News:Valero, Ports of Indiana Celebrate Restart of Ethanol Plant 3Health News:Electrical Pulses to Scalp May Boost Memory: Study 2Health News:Electrical Pulses to Scalp May Boost Memory: Study 3
(Date:8/28/2014)... alert the world to Global Warming, has called for ... underground. He says that Carbon Capture, combined with limits ... avoid global warming getting out of control over the ... made the call during his presentation to the International ... meeting to discuss Carbon Capture and Storage. , ...
(Date:8/28/2014)... (LMU) in Munich have assigned a number of ... arthropods. These animals lived in shallow marine habitats ... found in Jurassic strata. , Before they ... habitat and were fossilized some 435 million years ... the Silurian seas although they were not ...
(Date:8/27/2014)...  WaferGen Bio-systems, Inc. (NASDAQ: WGBS) today announced that ... of units of common stock and warrants at a ... $20 million, prior to deducting underwriting discounts and commissions ... and warrants are immediately separable and will be issued ... offering consists of 2,000 shares of common stock and ...
Breaking Biology News(10 mins):Global warming pioneer calls for CO2 to be taken from atmosphere and stored underground 2Paleontology: Oldest representative of a weird arthropod group 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3
Other Contents